Heart Failure Study Shows High Doses of Ace Inhibitor Zestril (Lisinopril) Provide Significant Therapeutic Benefits
AstraZenecaFor the five million Americans who suffer from congestive heart failure, a new study shows that patients taking high doses of the angiotensin converting enzyme (ACE) inhibitor Zwstril (lisinopril) may live longer and be hospitalized less often than those on low dose therapy. The results were announced today at the 47th Annual American College of Cardiology (ACC) Scientific Session.